title: Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis.
abstract: Observational studies of the effect of beta-interferon (IFNbeta) on accumulation of fixed disability in relapsing remitting multiple sclerosis (RRMS) in clinical practice have been difficult to interpret due to bias. The aim of this study of 175 RRMS patients was to use Bayesian analysis to establish whether IFNbeta attenuates disability relative to a cohort of matched historical control subjects from the Sylvia Lawry Centre for MS Research. A sensitivity analysis was based on a range of prior probability distributions for IFNbeta efficacy derived from a published meta-analysis of randomised controlled trials (RCTs) of IFNbeta, and the data were interpreted both unmodified and using variance inflation and point estimate bias correction; the corrected data interpreted in the light of the most likely prior probability distribution yielded a 95 % posterior credible interval for the odds ratio of accumulation of fixed disability after two years of IFNbeta therapy of 0.52, 0.94. It is concluded that two years of IFNbeta therapy for RRMS reduces accumulation of fixed disability in clinical practice.
authors: Department of Neurology, St. Vincent's University Hospital, Dublin 4, Ireland.
authors: Killian
authors: K
authors: O'Rourke
authors: Cathal
authors: C
authors: Walsh
authors: Michael
authors: M
authors: Hutchinson
mesh_terms: D000293:Adolescent; D000328:Adult; D001499:Bayes Theorem; D016022:Case-Control Studies; D015331:Cohort Studies; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D019370:Observation; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic
chemical_list: D007155:Immunologic Factors; D016899:Interferon-beta
references: J Natl Cancer Inst. 1996 Nov 20;88(22):1645-51
references: 8931608
references: Ann Neurol. 1983 Mar;13(3):227-31
references: 6847134
references: Am J Med. 1982 Feb;72(2):233-40
references: 7058834
references: Acta Neurol Scand. 2000 Oct;102(4):209-17
references: 11071104
references: J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):450-7
references: 10727480
references: Ann Neurol. 2002 Oct;52(4):400-6
references: 12325067
references: J Neurol. 2005 Jul;252(7):795-800
references: 15772741
references: Neurology. 1995 Jul;45(7):1277-85
references: 7617182
references: Ann Neurol. 1996 Mar;39(3):285-94
references: 8602746
references: Neurology. 2005 Oct 11;65(7):1066-70
references: 16217060
references: J Neurol Sci. 2001 Aug 15;189(1-2):13-21
references: 11535229
references: Lancet. 1998 Nov 7;352(9139):1498-504
references: 9820297
references: BMJ. 1996 Sep 7;313(7057):603-7
references: 8806254
references: Brain. 1999 Oct;122 ( Pt 10):1941-50
references: 10506095
references: Mult Scler. 2005 Feb;11(1):46-50
references: 15732266
references: Lancet. 2004 May 22;363(9422):1728-31
references: 15158638
references: JAMA. 1994 Jul 13;272(2):125-8
references: 8015122
references: Mult Scler. 2003 Oct;9(5):451-7
references: 14582768
references: Neurology. 1983 Nov;33(11):1444-52
references: 6685237
references: Lancet. 2003 Feb 15;361(9357):545-52
references: 12598138
references: Arch Intern Med. 1992 Mar;152(3):507-12
references: 1546913
references: Eur J Neurol. 2003 Nov;10(6):671-6
references: 14641512
references: Brain. 1989 Dec;112 ( Pt 6):1419-28
references: 2597989
references: J Neurol Neurosurg Psychiatry. 2003 Dec;74(12):1689-92
references: 14638892
references: J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):946-9
references: 12810786